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Abstract
Background: The increasing occurrence of multidrug resistant (MDR) bacteria arises at a time when there is a lack
of antibiotics active against these pathogens and few new antimicrobials are in the pipelines of the pharmaceutical
industry. Treatment of ventilator-associated pneumonia (VAP) caused especially by MDR Gram-negative bacilli (GNB)
represents a real challenge due to the dearth of treatment options.
Methods: We searched the medical literature relevant about management of ventilator-associated pneumonia
caused by multi-drug resistant pathogens including GNB and methicillin-resistant S. aureus.
Results: Empirical therapy should be prescribed based on the local pattern of susceptibilities. Colistin and tigecycline
are in many cases the unique options for the treatment of many episodes of VAP caused by MDR-GNB. Tigecyline
(not licensed for treatment of pneumonia) should be used with an initial bolus of 200 mg followed by 100 mg
every 12 h. The need for a loading dose and the administration of high doses of colistin (9 million IU/day in two
or three doses) is currently accepted. Vancomycin has been considered the treatment of choice for pneumonia
due to MRSA although linezolid may provide higher rate of clinical cure for MRSA VAP with a good safety profile.
The initial antibiotic treatment must be reassessed and simplify in accordance of culture results.
Conclusions: Empirical treatment of VAP due to MDR pathogens should be based on knowledge of local ecology.
A strategy combining early high doses of effective agents with subsequent simplification in the light of microbiologic
information is recommended.
Introduction
Ventilator-associated pneumonia (VAP) is one of the most
dreaded nosocomial infection. VAP appears to have a
low attributable mortality although episodes caused by
multi-drug resistant (MDR) pathogens is associated
with a significant attributable mortality [1,2]. Potential
MDR pathogens include: P. aeruginosa, Acinetobacter spp,
extended spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae, Klebsiella-producing carbapanamase
strains, Stenotrophomonas maltophilia, and methicillin-
resistant S. aureus (MRSA).
In critically ill patients, the susceptibility of the bacteria
isolated in a VAP depends on the duration of stay in
the ICU and on mechanical ventilation as well as the
previous use of antibiotics [3]. VAP has been conventionally
classified into early and late onset. Early-onset VAP occurs
within less than 96 hours of ICU admission and is generally
due to antimicrobial-sensitive bacteria. Late-onset VAP
occurs after 96 hours of ICU admission and may be caused
by MDR pathogens. Other risk factors of MDR pathogens
include prior antibiotic use within the preceding 90 days,
frequency of antibiotic resistance in the community or
hospital, and the immunocompromised state [4]. However,
different studies have described a high rate of VAP due to
MDR pathogens in episodes occurring in the first days
of mechanical ventilation highlighting the importance
of local ecology [5-7].
Diagnosing of VAP is difficult because it requires a
thorough assessment of clinical data, radiological findings,
and microbiological results. There are no foolproof tools
to determine whether the patient has a VAP. When the
clinical suspicion of VAP is high, empirical antimicrobial
therapy must be initiated promptly because both delayed
and inadequate treatments have been associated with
increased rate of morbidity and mortality [4]. Nevertheless,
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one third of the patients with VAP only exhibit clinical
criteria of sepsis [8]. In patients with no signs of severe
sepsis or septic shock and no organisms present on
Gram’s staining, antimicrobial therapy can be withheld
pending culture results [9,10].
Current guidelines recommend empirical coverage of
Gram-negative bacilli (GNB) with a third or forth gen-
eration cephalosporin, piperacillin-tazobactam or a car-
bapenem in combination with a fluoroquinolone or an
aminoglycoside [11]. However, the problem arises when
a high proportion of the GNB are resistant to these
antibiotics. One of the consequences of a greater
prevalence of antimicrobial resistance is an increased
recognition of inadequate antimicrobial treatment of
infection. Few alternatives are available for treatment
of these multi-drug resistant GNB.
Antibiotics for MDR-GNB
Carbapenems
Carbapenems have constituted the mainstay of VAP for
many years. Imipenem, meropenem and doripenem have
similar spectrum although doripenem is the most active
carbapenem against P aeruginosa [12]. No carbapenem
seems to be superior to another in clinical trials that
have evaluated these agents in late-onset VAP [13,14] or
in VAP caused by P aeruginosa [15]. Optimization of
carbapenem dosages (extended infusion of meropenem
or doripenem) achieves improved pharmacokinetic and
pharmacodynamic target attainments and is associated
with higher rate of clinical cure in VAP [16,17]. Dual-
carbapenem therapy (ertapenem plus meropenem or
doripenem) against KPC-producing K. pneumoniae has
been evaluated in animal models [18]. The beneficial
effect may be related to the KPC enzyme’s preferential
affinity for ertapenem hindering doripenem or mero-
penem degradation and allowing the action of this
carbapenem. A successful recovery with the use of this
combination in a patient with bacteremic VAP due to
pan-resistant KPC-producing K. pneumoniae has been
recently reported [19].
Colistin
Polymyxins are a group of polypeptide cationic antibiotics.
Only polymyxin B and polymyxin E (colistin) are used
in clinical practice. Colistin acts in a way that does not
promote cross-resistance and is unlikely to be associ-
ated with swift selection of resistant strains. Nowadays,
colistin is the antimicrobial with the greatest level of
in vitro activity against multi-drug resistant GNB in-
cluding A baumannii, P aeruginosa, extended spectrum
beta-lactamase (ESBL)-producing Enterobacteriaceae or
Klebsiella-producing carbapanamase strains. However, some
GNB such as Proteus spp, Providencia spp, Morganella
morganii and Serratia marcescens are resistant [20].
Over the last decade, our knowledge on the clinical
pharmacokinetic of colistin has increased considerably.
Several studies have pointed out that intravenous admin-
istration of colistimethate sodium (CMS) may lead to
suboptimal plasma concentrations and is associated with
higher mortality. Thus, low daily dosage of i.v. colistin has
been identified as an independent predictor of mortality
(OR 0.81, 95% CI 0.68-0.96) in patients with VAP [21]. In
13 critically ill patients with VAP caused by GNB, colistin
was undetectable in BAL performed at 2 h after the start
of the CMS infusion (2 million IU 8-hourly) [22].
The need for a loading dose and the administration of
high doses of colistin has been recently demonstrated.
Plachouras et al [23] described in 18 critically ill patients
receiving 3 million IU of CMS 8-hourly that plasma
colistin concentrations were sub-optimal for 2-3 days
before reaching steady state. The authors recommended a
loading dose of 9 million IU and 4.5 million IU 12-hourly
because colistin displayed a half-life that was significantly
long in relation to the dosing interval. The clinical efficacy
and the lack of toxicity of this regimen have been con-
firmed in a series of critically ill patients with bacteremia
or VAP caused by MDR-GNB [24]. In contrast, a loading
dose of 6 MU may be adequate [25], and our preliminary
results indicate that a loading dose of 4.5 UI of colistin
may be sufficient to reach therapeutic levels in non-obese
critically ill patients with MDR-VAP [26].
The efficacy of colistin in VAP caused by MDR-GNB
has been demonstrated in several retrospective and
prospective series [27-30]. These studies have evaluated
colistin mostly in the directed therapy being scarce the
information about the use of this antibiotic empirically.
A multicenter randomized clinical trial (RCT) that is cur-
rently ongoing has been designed to assess the efficacy and
safety of colistin compared to meropenem in the empirical
therapy of VAP with high suspicion of MDR-GNB [31].
While awaiting the results of this RCT, the empirical use of
colistin may justify in institutions where there is a high rate
of infections due to MDR-GNB [32].
Synergistic activity of colistin and rifampicin combin-
ation against different GNB has been documented in
experimental models [33,34]. Nevertheless, a recent RCT
failed to demonstrate clinical superiority of the combin-
ation of colistin plus rifampicin over monotherapy with
colistin in patients with severe infections (two-thirds with
VAP) caused by extensively drug-resistant Acinetobacter
baumannii [35]. The results were identical in another
clinical trial that compared colistin plus rifampicin with
colistin in patients with VAP caused by carbapenem-
resistant Acinetobacter baumannii [36].
Different in vitro studies have documented the existence
of a potent synergism of the combination of colistin with a
glycopeptide against carbapenem-resistant A baumannii
[37,38]. In a retrospective series, we did not find clinical
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benefit of this combination in patients with A baumannii
VAP and observed a higher rate of renal failure in com-
parison with monotherapy with colistin [39]. Conversely, a
multicenter study that included a heterogeneous group of
infections caused by different GNBs concluded that
therapy with colistin plus a glycopeptide ≥ 5 days was a
protective factor for 30-day mortality [40].
Tigecycline
Tigecycline is a broad spectrum antibiotic with potent
in vitro activity against anaerobic and aerobic Gram-
positive bacteria and Gram-negative pathogens with the
exceptions of P aeruginosa and Proteus ssp. Tigecycline
is active against A. baumannii, including some colistin-
resistant strains [41].
Notwithstanding, tigecycline is not licensed for treatment
of hospital-acquired pneumonia, including VAP. In a mul-
ticenter, randomized, double-blind, study that compared
50 mg every 12 h (loading dose 100 mg) with imipenem,
tigecycline was inferior to the imipenem/cilastatin regimen
for the clinically evaluable population. This difference
appeared to have been caused by results in VAP patients
in whom there was a higher mortality in the tigecycline
group that did not reach statistical significance [42].
Nevertheless, small series and observational studies have
reported acceptable results with the use of tigecycline
for MDR-VAP [43,44]. Very recently, in a matched cohort
analysis adjusted for propensity score, episodes of A
baumannii VAP treated with tigecycline had a statistically
significant excess of mortality in comparison to patients
treated with colistin. The excess mortality of tigecycline
was significant only among those with MIC >2 μg/mL, but
not for those with MIC ≦ 2 μg/mL. All isolates were
susceptible to colistin [45].
Dose of tigeclycline approved for intra-abdominal and
skin and soft tissue infections (50 mg every 12 h with a
loading dose of 100 mg) does not achieve adequate
concentrations for pulmonary infections [46]. A recent
randomized phase 2 trial has evaluated the clinical efficacy
of two high-dosage tigecycline regimens versus imipenem-
cilastatin for treatment of hospital-acquired pneumonia.
Although the number of patients included is too low to
draw conclusions in terms of mortality, 200 mg followed
by 100 mg every 12 h achieved the greatest rate of clinical
cure [47]. Therefore, it seems necessary to administer, in
an episode with suspicion of extremely resistant GNB, this
high dose in order to avoid insufficient levels in lung tissue
and, at least empirically, always in combination therapy
(a carbapenem or colistin are probably the best options).
Fosfomycin
Fosfomycin is an “old” antimicrobial that shows potent
bactericidal action against many Gram-negative and
Gram-positive pathogens. The drug shows little toxicity.
Regrettably, resistance develops rapidly when fosfomycin is
used as monotherapy. Since fosfomycin shows synergistic
action with other antimicrobials it is an interesting option
to treat a wide range of infections, including VAP caused
by MDR pathogens [48].
This antibiotic has gained recently relevance for the
treatment of extensively resistant GNB especially K pneu-
monia or P aeruginosa due to the lack of valid alternatives.
A recent series has reported an acceptable response in
patients with VAP treated with high doses (24 g/day)
of fosfomycin always in combination with other anti-
microbials [49].
Antibiotics for resistant Gram-positive cocci
Empirical coverage of MRSA is less troublesome. Vanco-
mycin has been considered the treatment of choice for
pneumonia due to MRSA [4]. Almost all MRSA isolates
are susceptible to vancomycin and only anecdotal cases of
MRSA resistant to this glycopeptide have been reported.
However, an interesting issue to keep in mind is the MIC
of MRSA to vancomycin. Several studies in patients
with MRSA pneumonia or bacteremia (mainly from
lung source) have observed a higher rate of treatment
failure and mortality in episodes with MIC ≥ 1.5 mg/L
treated with vancomycin [50,51]. Lung infection has been
identified as an independent predictor of treatment failure
in MRSA bacteremia treated with vancomycin and not
explained by MIC [52], perhaps reflecting the poor pene-
tration of this antibiotic into the lung tissue [53].
Current guidelines recommend a loading dose of 25-
30 mg/kg followed by vancomycin dosages of 15-20 mg/kg
given every 8-12 hours for patients with normal renal
function [54]. Monitoring of trough concentrations is
necessary after the forth dose to maintain serum trough
concentrations of 15-20 mg/L increase efficacy and im-
prove clinical outcomes. An AUC to MIC ratio ≥400 has
been shown to predict more favorable microbiological and
clinical outcomes in cases of S. aureus pneumonia [55].
Teicoplanin might be an acceptable alternative to treat
pneumonia caused by MRSA. However, the administration
of high teicoplanin doses (12 mg/kg teicoplanin every 12 h
the first 2 days followed by 12 mg/kg once daily) is needed
to reach sufficient antibiotic concentrations in lung tissues
at steady state [56]. We do not recommend teicoplanin for
VAP due to the uncertainties about the correct doses,
impossibility of level measurements, and the availability
of alternatives such as vancomycin or linezolid.
Linezolid has been shown to have a better pharmacoki-
netic profile than vancomycin [57]. The post hoc analysis
of two randomized, double-blind studies concluded that
linezolid therapy was associated with significantly better
clinical cure and survival rates than therapy with vanco-
mycin in the subgroup of patients with MRSA VAP
[58]. In a recent double-blind, controlled trial, linezolid,
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compared with vancomycin, achieved a higher clinical and
microbiological response rate (the latter was not statisti-
cally significant) despite vancomycin dose optimization,
together with a lower incidence of all types of renal
adverse effects in patients with MRSA pneumonia.
However, mortality was unaffected [59]. Limitations of
this study include imbalanced distribution of medical
comorbidities and the number of patients excluded to
reach the per-protocol group.
Although tigecycline is active against MRSA, clinical
cure of cases of MRSA was lower with tigecycline than
with the comparator in the clinical trial that evaluated
this antibiotic in hospital-acquired pneumonia [42]. There-
fore, we do not advocate the use of tigecycline for MRSA
pneumonia and a specific antibiotic against this Gram-
positive bacterium is necessary.
Ceftaroline is a cephalosporin with broad gram-positive
activity, including MRSA. Its gram-negative activity in-
cludes common respiratory pathogens and members of
the Enterobacteriaceae. However, ceftaroline is currently
only approved for acute bacterial skin infections and
community-acquired pneumonia. This new cephalosporin
has a promising role in the treatment of VAP but clinical
data are not currently available. It should be used in com-
bination with another antimicrobial to cover GNB such as
P aeruginosa or ESBL-producing Enterobacteriaceae.
Nebulized antibiotics
The administration of nebulized antibiotics has been pro-
posed to provide high levels of the drug in the lung and to
reduce the systemic toxicity associated with intravenous
antibiotics. The concentration in the respiratory secretion
of the nebulized antibiotic may be 20 to 100 fold greater
than the in-vitro MIC of the organisms being treated [60].
Large randomized trials are needed to define the impact
on clinical outcomes of nebulized antibiotics as adjunctive
therapy in MDR-VAP.
Table 1 Decalogue to treat VAP caused by MRD pathogens
1 Antimicrobials used in the empirical regimens should be chosen based on the local pattern of susceptibility.
2 Initiation of antimicrobial therapy should not be delayed in patients with high probability of VAP especially if the infection originates
severe sepsis or septic shock.
3 In patients with no signs of severe sepsis or septic shock and no organisms present on Gram’s staining, antimicrobial therapy can be withheld
pending culture results.
4 When a high rate of episodes is caused by extremely resistant GNB, empirical use of colistin and/or tygecycline may be justified.
5 The inclusion of a carbapenem (in extended infusion) in this empirical therapy seems reasonable especially for pathogens not covered by
these antibiotics.
6 Addition of vancomycin or linezolid is recommended is Units with high prevalence of MRSA (>10% of episodes caused by MRSA).
7 The initial antibiotic treatment must be reassessed when the culture results are available. Depending on the clinical progress and the
microbiological findings, clinicians should adjust therapy accordingly.
8 In episodes caused by very-difficult-to-treat GNB, it seems prudent to maintain combination therapy (if possible) until the clinical course
appears clearly favorable.
9 Nebulized antibiotics should be considered in the directed therapy of patients who are nonresponsive to systemic antibiotics or in episodes
caused by GNB strains with high CMI (intermediate).
10 Not all patients with MDR-VAP have to be treated for two weeks. Courses of treatment should be individualized. Procalcitonin may be of aid
to stop antibiotics after eight days of adequate antimicrobial therapy.
Table 2 Recommended doses of antimicrobials use in VAP caused by MDR pathogens in patients with normal
renal function
Antibiotic Loading dose Daily dose Observations
Imipenem* Not required 1 g/6-8 h Extended or prolonged infusion is not possible due to drug instability
Meropenem* Not required 1-2 g/8 h Extended infusion (3-4 hours) is recommended.
Doripenem* Not required 500 mg-1 g/8 h Extended infusion (3-4 hours) is recommended.
Colistin* 4.5-9 UI 9 UI/day in 2 or 3 dose Loading dose is necessary.
Tigecycline 200 mg 100 mg/ 12 h Without approval by regulatory agencies.
Fosfomycin* Not required 24 g/day (in four doses) Always in combination therapy.
Vancomycin* 25-30 mg/kg
(based on ABW)
15-20 mg/kg (based on ABW)
every 8-12 hours
Monitor trough concentrations after the forth dose; serum trough levels
of 15-20 mg/L for MRSA VAP.
Linezolid Not required 600 mg/ 12 h It should be changed to vancomycin in the directed therapy of patients
with good clinical evolution and S aureus with vancomycin MIC ≤ 1 mg/L.
*Dose adjustment is necessary in case of renal dysfunction.
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Although diverse antibiotics have been nebulized, the
most extensive experience exists with aminoglycosides
and colistin. The use of appropriate devices is essential
to assure clinical and microbiological utility of nebulized
antibiotics. During mechanical ventilation, high amounts
of the particles dispersed by conventional nebulizers re-
main in the ventilatory circuits and the tracheobronchial
tree and, therefore, less drug is available in the alveolar
compartment.
The use of aerosolized colistin for multi-drug resistant
GNB pneumonia increases cure rates and may be reason-
ably efficacious and safe [61]. The use of inhaled colistin
was independently associated with clinical cure in a
retrospective study (OR 2.53, 95% CI 1.11-5.76) although
mortality was unaffected. Nevertheless, other studies have
concluded that the use of aerosolized colistin in conjunc-
tion with intravenous colistin did not provide additional
therapeutic benefit to patients with MDR VAP due to
gram-negative bacteria [62]. Moreover, a randomized
controlled trial of nebulized CMS as adjunctive therapy
of ventilator-associated pneumonia caused by GNB failed
to demonstrate beneficial effect on clinical outcome [63].
Regarding aminoglycosides, several studies have evaluated
tobramycin or amikacin with promising results [64,65].
Duration of treatment
There is no consensus regarding the duration of anti-
biotic treatment for patients with VAP due to MDR. In a
randomized clinical trial that included patients with VAP
and adequate empirical antimicrobial therapy, short-course
(8 days) treatment of VAP has no difference in terms of
mortality compared to long-course (15 days) treatment.
In VAP caused by non-fermenting gram-negative bacilli
including P aeruginosa, rate of recurrence was significantly
higher (40.6% vs 25.4%) in patients receiving 8 days of
treatment [66]. A recent meta-analysis of four RCTs also
concluded that a short-course of antibiotic may be enough
to treat VAP although the issue of length of therapy in
MDR VAP has not been specifically evaluated [67]. A pro-
spective study showed that a procalcitonin-based strategy
(recommending that physicians stop antibiotics when
the procalcitonin concentration was <0.5 ng/mL, or had
decreased by ≥80%) did not negatively influence outcomes
although the subgroup of patients with MDR-VAP was
not specifically assessed [68].
Conclusions
Empirical treatment of a VAP with a high probability of a
MDR pathogen is one of the major challenges facing an
intensivist. Similarly, it is complex the directed therapy
especially when a very-difficult-to-treat MDR-GNB (i.e.
carbapenemase-producing K. pneumoniae, extremely drug-
resistant A baumannii or P aeruginosa) is confirmed as the
etiology of the pneumonia. Our personal point of view for
the treatment of VAP caused by MDR pathogens is sum-
marized as a Decalogue in Table 1. Doses of antibiotics
recommended for these infections are depicted in Table 2.
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